Compare AstraZeneca plc (AZN) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs PubMatic Inc — how do they compare? AstraZeneca plc trades at $166.66 (market cap $253.13B), while PubMatic Inc trades at $13.52 (market cap $635.81M). The key difference: AstraZeneca plc is far larger — about 398.1× PubMatic Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| AZN | PUBM | |
|---|---|---|
Market Cap | $253.13B | $635.81M |
Sector | Health | Technology |
52-Week High | $209.48 | $13.83 |
52-Week Low | $137.44 | $6.28 |
Enterprise Value | $279.37B | $533.31M |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
PubMatic trades at $13.57, up 0.15% with a bullish technical signal from moving averages. The company reported Q1 2026 earnings that beat expectations despite a net loss, with revenue of $282.93M in 2025 and a gross margin of 63.22%. Recent news highlights partnerships expanding AI-driven ad tech in CTV and international markets, supporting growth initiatives.
Outlook is mixed with strong analyst buy ratings (50%) and a $17.00 consensus target offering 25% upside, but profitability concerns persist with negative net margins and high P/E of 132. Key risks include competitive pressures and reliance on digital ad spending cycles, requiring monitoring of earnings turnaround progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
